KRAS and neoplasm: KRAS mutation upregulated lipase H (LIPH) expression, enhancing the infiltration of tumor-associated macrophages (TAMs), Treg cells, and Th2/Th1 cells into the TME, while reducing the infiltration of CD8+ T cells and Th1 cells; this further contributed to tumor recurrence, worsening of histological grade, and poorer overall survival (Zhuang et al., 2022).